Antibody gene-based prophylaxis and therapy for biodefence

Human Vaccines

Volumn 4, Issue 1, 2008, Pages 74-78

  Hu, Wei Gang ^a   Nagata, Les P ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

Antibody gene; Biodefence; In vivo delivery; Prophylaxis; Therapy

Indexed keywords

ANTIBODY; VACCINE;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; BIOLOGICAL WARFARE; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOTHERAPY; INFECTION; INFECTION PREVENTION; NOTE; PASSIVE IMMUNIZATION; TRANSGENE; VACCINATION;

EID: 44649090031     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.1.4778     Document Type: Note

References (47)

1. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen Jr EM. Biological warfare: A historical perspective. Jama 1997; 278:412-7.
2. Update: Investigation of bioterrorism-related inhalational anthrax-Connecticut. Morb Mortal Wkly Rep CDC Surveill Summ 2001.
3. Ricin: Ricin Overview. 2005.
4. Little SF, Ivins BE, Fellows PF, Friedlander AM. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infection and Immunity 1997; 65:5171-5.
5. Kobiler D, Gozes Y, Rosenberg H, Marcus D, Reuveny S, Altboum Z. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infection and Immunity 2002; 70:544-60.
6. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America 2002; 99:11346-50.
7. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infection and Immunity 1997; 65:3743-52.
8. Hill J, Copse C, Leary S, Stagg AJ, Williamson ED, Titball RW. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infection and immunity 2003; 71:2234-8.
9. Hill J, Leary SE, Griffin KF, Williamson ED, Titball RW. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infection and Immunity 1997; 65:4476-82.
10. Drabick JJ, Narayanan RB, Williams JC, Leduc JW, Nacy CA. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. The American Journal of the Medical Sciences 1994; 308:83-7.
11. Fulop M, Mastroeni P, Green M, Titball RW. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 2001; 19:4465-72.
12. Rhinehan-Jones TR, Fortier AH, Elkins KL. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infection and Immunity 1994; 62:3129-37.
13. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 1999; 254:71-80.
14. Ramirez JC, Tapia E, Esteban M. Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. The Journal of General Virology 2002; 83:1059-67.
15. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, Huggins JW, Schmidt JJ, LeDuc JW, Perers CJ. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996; 11:135-40.
16. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. Journal of Virology 2001; 75:4649-54.
17. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, Perers CJ, Parren PW, Burton DR. Ebola virus can be effectively neutralized by antibody produced in natural human infection. Journal of Virology 1999; 73:6024-30.
18. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. Journal of Virology 2002; 76:6408-12.
19. Hu WG, Chau D, Wu J, Jager S, Nagata LP. Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus. Vaccine 2007; 25:3210-4.
20. Phillpotts RJ, Jones LD, Howard SC. Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 2002; 20:1497-504.
21. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. The Journal of Infectious Diseases 2003; 188:5-12.
22. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. A critical role for induced IgM in the protection against West Nile virus infection. The Journal of Experimental Medicine 2003; 198:1853-62.
23. Chanh TC, Romanowski MJ, Hewetson JF. Monoclonal antibody prophylaxis against the in vivo toxicity of ricin in mice. Immunological Investigations 1993; 22:63-72.
24. Guo JW, Shen BF, Feng JN, Sun YX, Yu M, Hu MR. A novel neutralizing monoclonal antibody against cell-binding polypeptide of ricin. Hybridoma 2005; 24:263-6.
25. Pang LT, Kum WW, Chow AW. Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody. Infection and Immunity 2000; 68:3261-8.
26. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clinical Microbiology Reviews 1998; 11:1-26.
27. von Behring EASK. Ueber Zustandekommen der diphtherie-immunitat und der tetanus-immunitat bei thieren. S Dtsch Med Wochenschr 1890; 16:1113-6.
28. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7.
29. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994; 15:42-52.
30. McCafferry J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990; 348:552-4.
31. Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. Journal of Immunological Methods 1999; 231:11-23.
32. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nature Biotechnology 2005; 23:1073-8.
33. Spiegelberg HL. Biological activities of immunoglobulins of different classes and subclasses. Advances in Immunology 1974; 19:259-94.
34. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Advances in Pharmacology (San Diego, Calif) 1997; 40:137-206.
35. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K. Stable antibody expression at therapeutic levels using the 2A peptide. Nature Biotechnology 2005; 23:584-90.
36. Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z, Su C, Yang Q, Li Y, Sham J, Liu X, Wu M, Qian Q. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 2006; 12:6179-85.
37. Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996; 14:337-43.
38. Lorenzen N, Cupit PM, Einer-Jensen K, Lorenzen E, Ahrens P, Secombes CJ, Cunningham C. Immunoprophylaxis in fish by injection of mouse antibody genes. Nature Biotechnology 2000; 18:1177-80.
39. Kasuya K, Boyer JL, Tan Y, Alipui DO, Hackett NR, Crystal RG. Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. Mol Ther 2005; 11:237-44.
40. Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, Bogen B. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther 2004; 9:328-36.
41. Chen SY, Khouri Y, Bagley J, Marasco WA. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proceedings of the National Academy of Sciences of the United States of America 1994; 91:5932-6.
42. Zhou P, Goldstein S, Devadas K, Tewari D, Norkins AL. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: Targeting the endoplasmic reticulum and trans-Golgi network. J Immunol 1998; 160:1489-96.
43. Shaheen F, Duan L, Zhu M, Bagasra O, Pomerantz RJ. Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. Journal of Virology 1996; 70:3392-400.
44. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. The EMBO Journal 1995; 14:1542-51.
45. Levy-Mintz P, Duan L, Zhang H, Hu B, Dornadula G, Zhu M, Kulkosky J, Bizub-Bender D, Skalka AM, Pomerantz RJ. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. Journal of Virology 1996; 70:8821-32.
46. Jiang W, Venugopal K, Gould EA. Intracellular interference of tick-borne flavivirus infection by using a single-chain antibody fragment delivered by recombinant Sindbis virus. Journal of Virology 1995; 69:1044-9.
47. Sullivan DE, Mondelli MU, Curiel DT, Krasnykh V, Mikheeva G, Gaglio P, Morris CB, Dash S, Gerber MA. Construction and characrerization of an intracellular single-chain human antibody to hepatitis C virus non-structural 3 protein. Journal of Hepatology 2002; 37:660-8.